Literature DB >> 17615114

Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity.

Anna Forsby1, Bas Blaauboer.   

Abstract

Risk assessment of neurotoxicity is mainly based on in vivo exposure, followed by tests on behaviour, physiology and pathology. In this study, an attempt to estimate lowest observed neurotoxic doses after single or repeated dose exposure was performed. Differentiated human neuroblastoma SH-SY5Y cells were exposed to acrylamide, lindane, parathion, paraoxon, phenytoin, diazepam or caffeine for 72 hours. The effects on protein synthesis and intracellular free Ca2+ concentration were studied as physiological endpoints. Voltage operated Ca2+ channel function, acetylcholine receptor function and neurite degenerative effects were investigated as neurospecific endpoints for excitability, cholinergic signal transduction and axonopathy, respectively. The general cytotoxicity, determined as the total cellular protein levels after the 72 hours exposure period, was used for comparison to the specific endpoints and for estimation of acute lethality. The lowest concentration that induced 20% effect (EC20) obtained for each compound, was used as a surrogate for the lowest neurotoxic level (LOEL) at the target site in vivo. The LOELs were integrated with data on adsorption, distribution, metabolism and excretion of the compounds in physiologically-based biokinetic (PBBK) models of the rat and the lowest observed effective doses (LOEDs) were estimated for the test compounds. A good correlation was observed between the estimated LOEDs and experimental LOEDs found in literature for rat for all test compounds, except for diazepam. However, when using in vitro data from the literature on diazepam's effect on gamma-amino butyric acid (GABA)A receptor function for the estimation of LOED, the correlation between the estimated and experimental LOEDs was improved from a 10,000-fold to a 10-fold difference. Our results indicate that it is possible to estimate LOEDs by integrating in vitro toxicity data as surrogates for lowest observed target tissue levels with PBBK models, provided that some knowledge about toxic mechanisms is known.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17615114     DOI: 10.1177/0960327106072994

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  13 in total

1.  Evaluation of the importance of astrocytes when screening for acute toxicity in neuronal cell systems.

Authors:  E K Woehrling; E J Hill; M D Coleman
Journal:  Neurotox Res       Date:  2009-07-11       Impact factor: 3.911

2.  Single-cell ELISA and flow cytometry as methods for highlighting potential neuronal and astrocytic toxicant specificity.

Authors:  E K Woehrling; E J Hill; E E Torr; M D Coleman
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

3.  Current status and future directions for a neurotoxicity hazard assessment framework that integrates in silico approaches.

Authors:  Kevin M Crofton; Arianna Bassan; Mamta Behl; Yaroslav G Chushak; Ellen Fritsche; Jeffery M Gearhart; Mary Sue Marty; Moiz Mumtaz; Manuela Pavan; Patricia Ruiz; Magdalini Sachana; Rajamani Selvam; Timothy J Shafer; Lidiya Stavitskaya; David T Szabo; Steven T Szabo; Raymond R Tice; Dan Wilson; David Woolley; Glenn J Myatt
Journal:  Comput Toxicol       Date:  2022-03-17

4.  Integrated testing strategies for safety assessments.

Authors:  Thomas Hartung; Tom Luechtefeld; Alexandra Maertens; Andre Kleensang
Journal:  ALTEX       Date:  2013       Impact factor: 6.043

5.  Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach.

Authors:  Anne K Krug; Raivo Kolde; John A Gaspar; Eugen Rempel; Nina V Balmer; Kesavan Meganathan; Kinga Vojnits; Mathurin Baquié; Tanja Waldmann; Roberto Ensenat-Waser; Smita Jagtap; Richard M Evans; Stephanie Julien; Hedi Peterson; Dimitra Zagoura; Suzanne Kadereit; Daniel Gerhard; Isaia Sotiriadou; Michael Heke; Karthick Natarajan; Margit Henry; Johannes Winkler; Rosemarie Marchan; Luc Stoppini; Sieto Bosgra; Joost Westerhout; Miriam Verwei; Jaak Vilo; Andreas Kortenkamp; Jürgen Hescheler; Ludwig Hothorn; Susanne Bremer; Christoph van Thriel; Karl-Heinz Krause; Jan G Hengstler; Jörg Rahnenführer; Marcel Leist; Agapios Sachinidis
Journal:  Arch Toxicol       Date:  2012-11-21       Impact factor: 5.153

Review 6.  From QSAR to QSIIR: searching for enhanced computational toxicology models.

Authors:  Hao Zhu
Journal:  Methods Mol Biol       Date:  2013

7.  Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms.

Authors:  Jane C Caldwell; Marina V Evans; Kannan Krishnan
Journal:  J Toxicol       Date:  2012-07-30

8.  Translational research to develop a human PBPK models tool kit-volatile organic compounds (VOCs).

Authors:  M Moiz Mumtaz; Meredith Ray; Susan R Crowell; Deborah Keys; Jeffrey Fisher; Patricia Ruiz
Journal:  J Toxicol Environ Health A       Date:  2012

9.  MEGen: A Physiologically Based Pharmacokinetic Model Generator.

Authors:  George Loizou; Alex Hogg
Journal:  Front Pharmacol       Date:  2011-11-10       Impact factor: 5.810

10.  Application of physiologically based pharmacokinetic models in chemical risk assessment.

Authors:  Moiz Mumtaz; Jeffrey Fisher; Benjamin Blount; Patricia Ruiz
Journal:  J Toxicol       Date:  2012-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.